FATE THERAPEUTICS INC
Business
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies using proprietary induced pluripotent stem cell (iPSC) technology. The company engineers clonal master iPSC lines to produce uniform, multiplexed-engineered T-cell and natural killer cell therapies incorporating novel synthetic controls and targeting mechanisms. Its pipeline includes FT819 for systemic lupus erythematosus and other autoimmune diseases, FT825 for solid tumors (partnered with Ono Pharmaceutical), FT836 targeting MICA/B for solid tumors, FT839 for dual-CAR therapy, and FT522 for hematologic malignancies and autoimmune indications, with manufacturing in its GMP facility in San Diego.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue | 7 | 14 | 64 | 96 | 56 | |
| Research and development | 108 | 135 | 173 | 320 | 216 | |
| General and administrative | 47 | 74 | 81 | 84 | 57 | |
| Impairment loss | 0 | 15 | 0 | — | — | |
| Total operating expenses | 154 | 224 | 254 | 405 | 273 | |
| Loss from operations | −148 | −210 | −191 | −308 | −217 | |
| Interest income | 11 | 17 | 17 | 6 | 1 | |
| Change in fair value of stock price appreciation milestones | 244,000 | 819,000 | 3 | 20 | 4 | |
| Other income | 93,000 | 6 | 10 | 516,000 | 0 | |
| Total other income | 11 | 24 | 30 | 27 | 5 | |
| Net loss | −136 | −186 | −161 | −282 | −212 | |
| Unrealized gain (loss) on available-for-sale securities, net | −152,000 | 253,000 | 2 | −1 | −832,000 | |
| Comprehensive loss | −136 | −186 | −159 | −283 | −213 | |
| Net loss per share, Basic | −1.15 | −1.64 | −1.64 | −2.91 | −2.24 | |
| Net loss per share, Diluted | −1.15 | −1.64 | −1.64 | −2.91 | −2.24 | |
| Weighted-average common shares used to compute basic net loss per share | 119 | 114 | 98 | 97 | 95 | |
| Weighted-average common shares used to compute diluted net loss per share | 119 | 114 | 98 | 97 | 95 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 47 | 36 | 42 | 61 | 134 | |
| Accounts receivable | 916,000 | 4 | 2 | 38 | 9 | |
| Short-term investments | 157 | 243 | 273 | 375 | 482 | |
| Prepaid expenses and other current assets | 4 | 9 | 15 | 27 | 9 | |
| Total current assets | 209 | 292 | 332 | 502 | 633 | |
| Long-term investments | 1 | 28 | 980,000 | 5 | 101 | |
| Property and equipment, net | 57 | 64 | 97 | 110 | 92 | |
| Operating lease right-of-use assets | 42 | 47 | 62 | 66 | 71 | |
| Restricted cash | 10 | 10 | 15 | 15 | 15 | |
| Other assets | 0 | 9,000 | 9,000 | 33,000 | 33,000 | |
| Total assets | 319 | 441 | 506 | 706 | 921 | |
| Accounts payable | 3 | 9 | 5 | 8 | 9 | |
| Accrued expenses | 20 | 21 | 28 | 54 | 42 | |
| CIRM award liability, current portion | 8 | 0 | 0 | 4 | 3 | |
| Deferred revenue | 381,000 | 393,000 | 685,000 | 42 | 21 | |
| Operating lease liabilities, current portion | 5 | 7 | 6 | 6 | 6 | |
| Total current liabilities | 36 | 39 | 39 | 114 | 81 | |
| CIRM award liability, net of current portion | 2 | 5 | 0 | 0 | 800,000 | |
| Operating lease liabilities, net of current portion | 73 | 78 | 97 | 104 | 109 | |
| Stock price appreciation milestones | 283,000 | 527,000 | 1 | 4 | 24 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value; authorized shares - 5,000,000; Class A Convertible Preferred shares issued and outstanding - 2,755,086 at December 31, 2025 and December 31, 2024 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |
| Common stock, $0.001 par value; authorized shares - 350,000,000 at December 31, 2025 and 250,0000,000 at December 31, 2024; issued and outstanding - 115,359,735 at December 31, 2025 and 113,928,279 at December 31, 2024 | 115,000 | 114,000 | 99,000 | 97,000 | 96,000 | |
| Additional paid-in capital | 1,741 | 1,716 | 1,580 | 1,536 | 1,449 | |
| Accumulated other comprehensive income | 116,000 | 268,000 | 15,000 | −2 | −762,000 | |
| Accumulated deficit | −1,534 | −1,398 | −1,212 | −1,051 | −769 | |
| Total stockholders equity | 207 | 319 | 368 | 484 | 679 | |
| Total liabilities and stockholders equity | 319 | 441 | 506 | 706 | 921 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −136 | −186 | −161 | −282 | −212 | |
| Depreciation and amortization | 13 | 19 | 18 | 14 | 6 | |
| Stock-based compensation | 25 | 41 | 43 | 79 | 54 | |
| Accretion and amortization of premiums and discounts on investments, net | −4 | −9 | −11 | −256,000 | 5 | |
| Deferred revenue | −12,000 | −892,000 | −42 | −6 | −19 | |
| Loss on disposal of property and equipment | 9,000 | 942,000 | 0 | — | — | |
| Accounts receivable | 3 | −1 | 37 | −30 | −3 | |
| Prepaid expenses and other assets | 5 | 5 | 13 | −18 | −3 | |
| Accounts payable and accrued expenses | −9 | −2 | −29 | 14 | 6 | |
| Right-of-use assets and lease liabilities, net | −3 | −4 | −1 | −828,000 | 2 | |
| Net cash used in operating activities | −106 | −123 | −132 | −248 | −163 | |
| Proceeds from sale of property and equipment | 362,000 | 0 | — | — | — | |
| Purchases of property and equipment | −6 | −730,000 | −6 | −36 | −51 | |
| Purchases of investments | −195 | −318 | −359 | −405 | −968 | |
| Maturities of investments | 312 | 331 | 478 | 607 | 695 | |
| Net cash provided by investing activities | 111 | 12 | 113 | 167 | −324 | |
| Issuance of common stock from equity incentive plans, net of issuance costs | 0 | 295,000 | 85,000 | 9 | 21 | |
| Proceeds from public offering of common stock, net of issuance costs | 0 | 75 | 0 | — | — | |
| Proceeds from issuance of pre-funded warrants, net of issuance costs | 0 | 20 | 0 | 0 | 21 | |
| Proceeds from FT819 CIRM award | 1 | 5 | — | — | — | |
| Proceeds from FT836 CIRM award | 4 | 0 | — | — | — | |
| Net cash provided by financing activities | 5 | 100 | 85,000 | 9 | 453 | |
| Net change in cash, cash equivalents and restricted cash | 11 | −11 | −20 | −72 | −34 | |
| Purchases of property and equipment in accounts payable | 0 | 140,000 | 0 | 1 | 4 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is FATE THERAPEUTICS INC's CIK number?
FATE THERAPEUTICS INC's SEC CIK number is 0001434316 (1434316). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find FATE THERAPEUTICS INC's SEC filings?
All of FATE THERAPEUTICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did FATE THERAPEUTICS INC last report earnings?
FATE THERAPEUTICS INC (FATE) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-220691). This is FATE THERAPEUTICS INC's most recent earnings filing of record — not a forecast of its next earnings date.
What is FATE THERAPEUTICS INC's most recent earnings 8-K?
FATE THERAPEUTICS INC's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001193125-26-220691. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View FATE THERAPEUTICS INC's latest earnings 8-K →
Look up any company's CIK number →